Monday, March 21, 2016

BRIEF-BioMarin Pharmaceutical says late-stage study of pegvaliase meets primary endpoint

* Biomarin Phase 3 study of pegvaliase for phenylketonuria

(PKU) meets primary endpoint of blood phenylalanine (Phe)

reduction (p<0.0001)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)